Together with the demonstrated efficacy of TGFβ receptor 1 inhibitor against K19+ HCC‐CSCs, the detection of K19 expression using serum CYFRA 21‐1 before HCC treatment could allow for the actualization of individualized medicine for K19+ HCC patients. The gene discussed is KRT19; the disease is hepatocellular carcinoma.